Jun 03, 2020 / 06:00PM GMT
David Michael Steinberg - Jefferies LLC, Research Division - Specialty Pharma Analyst & Equity Analyst
Hello, everyone, and welcome to the Jefferies Healthcare Conference. I'm Dave Steinberg, analyst at Jefferies. And we are delighted to have with us this afternoon, the management of Nektar. With us today will be Wei Lin, who's Head of Development; and also Jennifer Ruddock, Head of Investor Relations. So there's a lot to talk about. ASCO just got over, EULAR is coming up. And with that, Wei Lin, take it away.
Wei Lin - Nektar Therapeutics - SVP & Head of Development
Okay. Well, thank you so much for the invitation to speak at Jefferies. So we've prepared a slide deck to share with the latest update about our status at Nektar Therapeutics.
And if we go on to the next slide, the Slide 3. So Slide 3 really highlights the breadth and scope of the program at Nektar. We have transitioned ourselves into an immuno-oncology company with a strong focus in our IL pipeline. And in addition, we have ongoing collaborations with both Eli Lilly and as well as
Nektar Therapeutics at Jefferies Healthcare Conference (Virtual) Transcript
Mar 05, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers